Yijun Zheng | Medicine | Best Researcher Award

Mr. Yijun Zheng | Medicine | Best Researcher Award

The Second Hospital & Clinical Medical School, Lanzhou University | China

Dr. Zheng Yijun is a dedicated medical researcher currently pursuing a PhD in Surgery at Lanzhou University. With a strong focus on the pharmacological actions of traditional Chinese medicine in cancer treatment, particularly gastric cancer, he has contributed to multiple papers, including two independent SCI publications. Dr. Zheng also serves as a reviewer for high-impact journals like Frontiers in Medicine and International Journal of Clinical Practice. He is actively involved in projects funded by the National Natural Science Foundation of China and collaborates on key provincial research initiatives.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Focus: Zheng has a clear focus on the prevention and treatment of gastric cancer through traditional Chinese medicine, a significant and relevant area of study in modern healthcare.

  • Academic Contributions: Zheng has independently authored two SCI papers, one of which has achieved a high citation rate, highlighting the impact of their work in the academic community.

  • Collaborative Research: Zheng has been involved in eight research projects, including two funded by the National Natural Science Foundation of China, which demonstrates involvement in high-impact research.

  • Peer Review Contributions: Serving as a reviewer for reputable journals such as SCI and Frontiers in Medicine showcases the recognition of Zheng’s expertise and their ability to contribute to the broader academic community.

  • Zheng Yijun demonstrates strong academic research in a promising and highly relevant field. With a focus on traditional Chinese medicine for cancer treatment, significant publications, and involvement in prestigious research projects, Zheng is well-positioned for consideration for the “Best Researcher Award.” However, expanding the breadth of their research network, increasing publication output, and gaining editorial experience would help to further solidify their candidacy for this award.

Education 🎓

Dr. Zheng is currently enrolled in the PhD program in Surgery at Lanzhou University. His academic journey is complemented by his extensive participation in research, including a review of Astragalus Polysaccharide’s pharmacological effects, published in Frontiers in Pharmacology. He has independently authored SCI papers that contribute to the field of traditional medicine’s role in cancer treatment.

Experience 💼

Dr. Zheng has participated in over eight research projects, two of which were funded by the National Natural Science Foundation of China. His work spans across the investigation of gastric cancer treatment and the pharmacological effects of traditional Chinese medicine. Additionally, Dr. Zheng has served as a reviewer for multiple high-impact journals, solidifying his expertise and credibility in the field.

Research Interest On Medicine 🔬

Dr. Zheng’s primary research interest is in the prevention and treatment of gastric cancer through traditional Chinese medicine. His research aims to provide a theoretical foundation for incorporating traditional medicine in cancer therapy, with a specific focus on polysaccharides and their pharmacological actions in tumor treatment.

Award 🏆

Dr. Zheng is a nominee for the Best Researcher Award at the Forensic Scientist Awards, due to his significant contributions to the field of medical research, particularly in the application of traditional Chinese medicine for tumor treatment. His innovative work and high citation rate highlight his impact in medical research.

Publications 📚

  1. Zheng Y, Ren W, Zhang L, Zhang Y, Liu D, Liu Y. “A Review of the Pharmacological Action of Astragalus Polysaccharide.” Front Pharmacol. 2020 Mar 24; 11:349. Link

    • Cited by: 348 articles (SCI citation)

  2. Zheng Y, Zhang Y, Wang Z, Guo X, Zhang L, Zhang Y. “Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer.” Discov Oncol. 2025 Apr 24; 16(1):606. Link

    • Cited by: 98 articles (SCI citation)

Conclusion 🌍

Dr. Zheng Yijun is an emerging leader in the field of medical research, particularly in the application of traditional Chinese medicine for cancer treatment. His dedication to advancing the understanding of gastric cancer and its treatment methods has already resulted in significant publications and recognition. As a nominee for the Best Researcher Award, his future in medical research looks promising, with continued contributions to the development of effective cancer therapies.

Jinhui Ma | Medicine | Best Researcher Award

Dr. Jinhui Ma | Medicine | Best Researcher Award

Associate doctor | China-Japan Friendship Hospital | China

A dedicated orthopedic specialist at China-Japan Friendship Hospital, Department of Bone and Joint Surgery, serving as an Associate Chief Physician, with profound expertise in diagnosing and treating complex bone and joint conditions. His commitment to advancing orthopedic care is exemplified by his contributions to clinical research, academic publications, and medical education.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Extensive Clinical Expertise: Specializes in diagnosing and treating complex bone and joint diseases, with a focus on early treatment of osteonecrosis of the femoral head and hip preservation techniques.
  • Research Excellence: Has led notable research projects, including one funded by the Beijing Natural Science Youth Fund and another by the China-Japan Friendship Hospital, while contributing to three National Natural Science Foundation projects.
  • Publication Record: As first and co-first author, has published 17 SCI articles and nearly 8 core journal articles, showcasing a strong contribution to the academic community.
  • Academic Contributions: Participated in compiling three orthopedic books and contributed to the development of two utility model patents.
  • Recognition and Awards: Recipient of the “Outstanding Scientific Research Award” and “Excellent Graduate” award from Peking University, reflecting research excellence.
  • Professional Engagement: Active involvement in academic exchanges at international and national conferences, including ASIA, COA, and BOA, highlights a global academic presence.
  • Leadership Roles: Holds multiple editorial board positions and leadership roles in prestigious medical societies, further emphasizing professional recognition.

Education 🎓

He earned his Doctorate in Clinical Medicine from the Peking University Health Science Center, where he was recognized as an “Excellent Graduate” and received the “Outstanding Scientific Research Award.”

Experience 💼

He honed his skills at Queen Mary Hospital of the University of Hong Kong, specializing in joint replacement technology. He has extensive experience in early treatment of osteonecrosis of the femoral head, hip preservation, osteoarthritis, rheumatoid arthritis, hip dysplasia, motor system injuries, total knee and hip replacements, as well as knee and shoulder arthroscopy.

Research Interests On Medicine 🔬

His research focuses on the diagnosis and treatment of osteonecrosis of the femoral head, hip preservation techniques, advancements in joint replacement, and improving outcomes in complex bone and joint diseases.

Awards 🏆

  • Excellent Graduate of Peking University
  • Outstanding Scientific Research Award, Peking University
  • First Prize, Battle of 100 Groups, China Association for Health Promotion and Education
  • Third Prize, Chinese Orthopedic Good Doctor Reading Contest, Chinese Journal of Bone and Joint Surgery
  • Excellent Prize, Speech Contest (Beijing), Editorial Committee of the Chinese version of JBJS

Publications 📖

He has authored 17 SCI articles and nearly 8 papers in core journals as the first or co-first author. Additionally, he participated in the compilation of three orthopedic books, such as “Osteonecrosis and Strategies for Diagnosis and Treatment of Joint Surgery.”

  • Title: Application, research hotspots, and shortcomings of degradable zinc-based alloys in bone defect repair and reconstruction

    • Authors: Liu Haoyang, Xie Qiang, Shen Mengran, Yue Debo, Wang Weiguo
    • Year: 2025
  • Title: Correction to: Extracellular Vesicles from BMSCs Prevent Glucocorticoid-Induced BMECs Injury by Regulating Autophagy via the PI3K/Akt/mTOR Pathway

    • Authors: Ma Jinhui, Shen Mengran, Yue Debo, Gao Fuqiang, Wang Bailiang
    • Year: 2024
  • Title: Editorial: New insight into immune cells in the development of non-traumatic osteonecrosis of the femoral head

    • Authors: Zhou Yu, Ma Jinhui, Zhang Qingyu, Wang Bailiang
    • Year: 2024
  • Title: Interleukin-33-mediated bone immunity

    • Authors: Shen Mengran, Ren Yansong, Zhou Yu, Ma Jinhui, Wang Bailiang
    • Year: 2023

Professional Contributions

He has led one Beijing Natural Science Youth Fund project, one China-Japan Friendship Hospital project, and contributed to three National Natural Science Foundation projects. His work also includes developing two utility model patents. Academically, he has presented at prestigious conferences like the Asian Association of Joint Replacement (ASIA), National Association of Orthopaedics (COA), and Beijing Orthopedic Association (BOA).

Professional Memberships 🔒

He serves as Secretary General of the Orthopedic Group of the Professional Committee of Translational Medicine of the Chinese Society of Microcirculation and holds memberships in:

  • Young and Middle-aged Editorial Committees of the Chinese Journal of Trauma, Chinese Journal of Reconstructive Surgery, Chinese Journal of Tissue Engineering, and Traditional Chinese Medicine Bone Setting.
  • Youth Working Committee of the Professional Committee of Translational Medicine, Chinese Society of Microcirculation.
  • Expert Committee on Bone Circulation and Osteonecrosis, Professional Committee of Shock Wave Medicine, Chinese Research Hospital Association.

Conclusion 🌟

His remarkable contributions to orthopedics, spanning clinical practice, research, and academic engagement, have made a lasting impact on the field. His passion for advancing orthopedic care and educating future generations continues to shape the future of bone and joint surgery.

Kevin Pak | Medicine | Best Researcher Award

Dr. Kevin Pak | Medicine | Best Researcher Award

Transplant Hepatology Fellow | UCLA | United States

Dr. Kevin C. Pak, M.D., is a distinguished transplant hepatologist affiliated with the Pflieger Liver Institute at the David Geffen School of Medicine at UCLA. With a strong background in internal medicine, gastroenterology, and hepatology, Dr. Pak has dedicated his career to advancing liver disease treatment and transplantation. His contributions to academic research and clinical practice have earned him recognition in the medical community.

Profile👤

Google Scholar

Scopus

Strengths for the Awards✨

Exceptional Research Contributions: Dr. Pak has an extensive portfolio of peer-reviewed publications in prestigious journals, covering a range of topics in gastroenterology, hepatology, and military medicine. His research on hepatitis B, hepatocellular carcinoma, liver transplantation, and inflammatory bowel disease is particularly noteworthy.

Clinical and Academic Leadership: As an Assistant Professor at USUHS and a former Chief Fellow in a gastroenterology fellowship, Dr. Pak has demonstrated strong mentorship and leadership in academic medicine. His contributions to teaching and training future physicians further emphasize his dedication to research and education.

Recognized Excellence: Multiple honors and awards, including the AASLD Emerging Liver Scholar Award (2019) and Resident Researcher of the Year, highlight his significant impact in the field. His invited presentations and poster sessions at national and international conferences further validate his research reputation.

Interdisciplinary and Military Medicine Contributions: His unique background in military medicine and research contributions in military healthcare settings (e.g., inflammatory bowel disease in active-duty personnel) provide a broader impact beyond civilian medicine.

Education 🎓

Dr. Pak began his academic journey at the United States Military Academy (USMA) in West Point, New York, earning a B.S. in Life Sciences. He then pursued his medical degree at the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. His postgraduate training includes an Internal Medicine Residency at Walter Reed National Military Medical Center, followed by a Gastroenterology & Hepatology Fellowship at Naval Medical Center San Diego. He further specialized in Transplant Hepatology through a fellowship at the Pflieger Liver Institute at UCLA.

Experience 💼

Dr. Pak has held several academic positions, including Assistant Professor of Medicine and Teaching Fellow at USUHS. He is actively involved in medical education, mentoring students and residents. His clinical expertise spans hepatology, transplant medicine, and gastroenterology, making him a key contributor to the field. Additionally, Dr. Pak has served in the military, where he provided medical services in critical care settings.

Research Interests On Medicine🔬

Dr. Pak’s research focuses on liver disease, hepatocellular carcinoma, chronic hepatitis B, and liver transplantation. He is particularly interested in optimizing treatment strategies for liver disease and investigating emerging therapies. His work contributes to advancements in hepatology, improving patient outcomes and clinical practices.

Awards 🏆

Dr. Pak has received numerous accolades throughout his career. He was honored with the Resident Researcher of the Year Award and the AASLD Emerging Liver Scholar Award. His excellence in teaching earned him the James J. Leonard Award for Excellence in Teaching. In his military service, he received commendations such as the Navy/Marine Corps Commendation Medal and the Joint Service Commendation Medal.

Publications 📚

Dr. Pak has authored multiple peer-reviewed publications in prestigious journals. His notable works include:

  • Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users

    • Authors: JD Vignali, KC Pak, HR Beverley, JP DeLuca, JW Downs, AT Kress, …
    • Publication Year: 2023
    • Citations: 38
  • Wilson’s disease and iron overload: pathophysiology and therapeutic implications

    • Authors: K Pak, S Ordway, B Sadowski, M Canevari, D Torres
    • Publication Year: 2021
    • Citations: 23
  • Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018

    • Authors: ZC Junga, A Mertz, K Pak, M Singla
    • Publication Year: 2023
    • Citations: 9
  • The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System

    • Authors: K Pak, Z Junga, A Mertz, M Singla
    • Publication Year: 2020
    • Citations: 6
  • State of the art: Test all for anti-hepatitis D virus and reflex to hepatitis D virus RNA polymerase chain reaction quantification

    • Authors: E Umukoro, JJ Alukal, K Pak, J Gutierrez
    • Publication Year: 2023
    • Citations: 5
  • Occult HBV infection: a case series at a military treatment facility

    • Authors: K Pak, S Ordway, D Torres
    • Publication Year: 2020
    • Citations: 4
  • An acute presentation of chronic gastric volvulus

    • Authors: K Pak, Z Junga, P Young
    • Publication Year: 2020
    • Citations: 4
  • Decades of cough: Delayed recognition of atypical cystic fibrosis in an adult patient

    • Authors: A Chandel, K Pak, S Dooley, K Salazar
    • Publication Year: 2020
    • Citations: 3
  • A small blemish: isotretinoin-induced microscopic colitis

    • Authors: LR Dukate, K Pak, W O’Connell, Z Junga
    • Publication Year: 2022
    • Citations: 2
  • A Case of Whipple’s Disease With Concomitant Esophageal Candidiasis

    • Authors: R Choi, A Pazevic, K Pak, M Skaret, A Bachmann, R Wilkerson
    • Publication Year: 2024
    • Citations: 1

Conclusion 🔍

Dr. Kevin C. Pak, M.D., is a dedicated physician, educator, and researcher in hepatology and gastroenterology. His commitment to advancing liver disease treatment, coupled with his academic and clinical expertise, makes him a key figure in the field. Through his research, mentorship, and clinical practice, Dr. Pak continues to contribute significantly to medical science and patient care.

Guowei Zheng | Medicine | Best Researcher Award

Prof. Dr. Guowei Zheng | Medicine | Best Researcher Award

Yunnan University of Chinese Medicine | China

Dr. Guowei Zheng is a distinguished professor at Yunnan University of Chinese Medicine, specializing in medicinal plant research. His work focuses on the collection, evaluation, and breeding of medicinal plant germplasm, as well as understanding plant responses to stress and exploring the biosynthetic pathways of medicinal ingredients in Chinese herbs. With extensive academic experience spanning over a decade, Dr. Zheng has made significant contributions to plant biology through multiomics approaches and phytochemical studies.

Profile👤

ORCID

Strengths for the Awards✨

  • Strong Research Output 📚

    • Dr. Zheng has published over 20 high-quality research papers in reputable journals, including BMC Plant Biology, Plant Diversity, PLoS ONE, and Phytochemistry.
    • His recent publications (2023–2025) demonstrate consistent research contributions, particularly in multi-omics, metabolomics, and medicinal plants.
  • Diverse Research Expertise 🔬

    • His work spans multiple critical areas, including medicinal plant breeding, stress response, and biosynthetic pathways of Chinese herbs.
    • His research on polyphyllin biosynthesis, glycerolipidome responses, and CO₂ elevation effects contributes to both fundamental science and applied plant biotechnology.
  • Academic and Professional Growth 📈

    • Rising from Assistant Professor (2010) to Full Professor (2021) at Yunnan University of Chinese Medicine.
    • Previous tenure at Kunming Institute of Botany, Chinese Academy of Sciences, a prestigious research institution.

🎓 Education

  • Ph.D. in Botany (2005–2010) – Kunming Institute of Botany, Chinese Academy of Sciences
  • Bachelor’s Degree in Biology (2001–2005) – Yunnan University

👨‍🏫 Experience

  • Professor (2021–Present) – Yunnan University of Chinese Medicine
  • Associate Professor (2018–2021) – Yunnan University of Chinese Medicine
  • Associate Professor (2016–2018) – Kunming Institute of Botany, Chinese Academy of Sciences
  • Assistant Professor (2010–2015) – Kunming Institute of Botany, Chinese Academy of Sciences

🔬 Research Interests On Medicine

  • 🌿 Medicinal Plant Germplasm – Collection, evaluation, and breeding of medicinal plant species
  • 💧 Plant Stress Response – Studying how medicinal plants adapt to environmental stressors
  • 🧪 Phytochemical Biosynthesis – Investigating synthesis pathways of medicinal compounds in Chinese herbs

🏆 Awards

(Please provide specific awards or recognitions received.)

📚 Publications

Dr. Zheng has published extensively in high-impact journals, contributing significantly to plant biology and phytochemistry.

  • Xu, P., Mi, Q., Zhang, X., Zhang, X., Yu, M., Gao, Y., Wan, X., Chen, Y., Li, Q., Chen, J., & Zheng, G. (2025). Dissection of transcriptome and metabolome insights into the polyphyllin biosynthesis in Paris. BMC Plant Biology, 25(1), 206.

  • Xu, P., Chen, J., Mi, Q., Li, W., Lu, Y., Luo, W., Yu, M., Zhang, X., Tu, Z., Xu, H., & Zheng, G. (2024). Metabolomics and transcriptomics profiling of three Paris species with varied polyphyllin compositions. Sci Data, 11(1), 1293.

  • Zheng, G., Li, W., Zhang, S., Mi, Q., Luo, W., Zhao, Y., Qin, X., Li, W., Pu, S., & Xu, F. (2023). Multiomics strategies for decoding seed dormancy breakdown in Paris polyphylla. BMC Plant Biology, 23(1), 247.

  • Li, W., Zhang, X., Pei, W., & Zheng, G. (2021). First Report of Root Rot Caused by Dactylonectria torresensis on Bletilla striata (Baiji) in Yunnan, China. Plant Disease, 0(0), PDIS-10-20-2166-PDN.

  • Liu, T., Chen, J., Xu, F., He, X., Yang, S., Zhu, Y., Li, W., & Zheng, G. (2020). Analysis of changes in the Panax notoginseng glycerolipidome in response to long-term chilling and heat. Plant Diversity, 42, 102-110.

  • Zheng, G., Cheng, J., & Li, W. (2020). Impacts of CO2 elevation on the physiology and seed quality of soybean. Plant Diversity, 42(1), 44-51.

  • Zheng, G., Luo, S., Li, S., Hua, J., Li, W., & Li, S. (2018). Specialized metabolites from Ageratina adenophora and their inhibitory activities against pathogenic fungi. Phytochemistry, 148, 57-62.

  • Zheng, G., & Li, W. (2017). Profiling membrane glycerolipids during gamma-ray-induced membrane injury. BMC Plant Biology, 17(1), 203.

  • Chen, J., Zheng, G., Zhang, Y., Aisa, H. A., & Hao, X. (2017). Phytotoxic Terpenoids from Ligularia cymbulifera Roots. Front Plant Sci, 7, 2033.

  • Zheng, G., Li, L., & Li, W. (2016). Glycerolipidome responses to freezing- and chilling-induced injuries: examples in Arabidopsis and rice. BMC Plant Biology, 16, 70.

  • Tang, T., Liu, P., Zheng, G., & Li, W. (2016). Two phases of response to long-term moderate heat: Variation in thermotolerance between Arabidopsis thaliana and its relative Arabis paniculata. Phytochemistry, 122, 81-90.

🔚 Conclusion

Dr. Guowei Zheng is a leading researcher in medicinal plant biology, with expertise in plant stress adaptation and bioactive compound biosynthesis. His contributions to plant sciences and phytochemistry continue to advance our understanding of medicinal herbs, making a significant impact on the field of traditional Chinese medicine and agricultural biotechnology.

Yang Xu | Medicine | Best Researcher Award

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.